In the News: CTL019 Wins FDA Panel Support, Driving with ADHD, High School Football, New Genetic Syndrome, Teen Bone Growth, Missed Nursing Care
Novartis Announces NEJM Publication Of Updated Analysis From ELIANA Trial Showing Longer-Term Durable Remissions With Kymriah™ In Children, Young Adults With r/r ALL
CAR T-Cell Therapy Hits Prime Time; Challenges Remain
Molecular structure of chimeric antigen receptor used for CTL019.... | Download Scientific Diagram
IJMS | Free Full-Text | CAR T-Cell Therapy in Hematological Malignancies | HTML
CAR-T cell therapy CTL019 gets FDA breakthrough therapy status | Pharma Intelligence
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials - The Lancet Haematology
CAR-T Phase II: 93% Complete Remission in Pediatric ALL
Clinical development of CAR T cell therapy in China: 2020 update | Cellular & Molecular Immunology
Novartis' CTL019 Applied for Clinical Trial in China to Officially Enter the Chinese Market |_Pharmasources.com
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B | DDDT
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia | NEJM
Frontiers | The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice | Immunology
Relationship between exposure and expansion of CTL019 cells and... | Download Scientific Diagram
What's happening under the hood: The cellular kinetics of a CAR T cell therapy
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B | DDDT
The FDA Approves the First CAR-T Cell Therapy for Cancer
Frontiers | Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward | Immunology
Primary analysis results from Novartis pivotal JULIET trial show Kymriah™
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany | Gene Therapy
Positive CHMP opinion for Novartis blood cancer drug | Science|Business
Building blocks for institutional preparation of CTL019 delivery - Cytotherapy
